EUPHORIA Blend (MOTS-c / BPC-157 / GHK-Cu / Kisspeptin-10): What It Is, Where to Get It Prescribed, and What It Costs

EUPHORIA is not a single molecule. It is four independently studied peptides — MOTS-c, BPC-157, GHK-Cu and kisspeptin-10 — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Each has its own literature, its own described mechanism and its own regulatory file at the FDA; the name is a brand name and appears in no journal. So "does EUPHORIA work" is four questions, because the combination has never been studied as a combination.

The rationale prescribers give is that the four cover systems that tend to decline together — metabolism, tissue repair, skin, and the body's own testosterone and oestrogen signalling — in a single injection. The vial label says "Kisspeptin"; the substance is the ten-amino-acid fragment, kisspeptin-10, the form the FDA has assessed.

GHK-Cu is 50 of the 72 mg in the vial, so by mass EUPHORIA is mostly a GHK-Cu preparation, and kisspeptin-10 is the smallest component by a wide margin at 2 mg. At the standard 0.25 mL dose that is 2.5 mg GHK-Cu, 0.5 mg MOTS-c, 0.5 mg BPC-157 and 0.1 mg kisspeptin-10. The ratio is fixed, which is the genuine trade-off of any blend.

EUPHORIA is not testosterone, not a steroid and not an anabolic agent; kisspeptin adds no hormone from outside, and the research describes it prompting the body's own pituitary and gonads. It is not a growth-hormone secretagogue, not a GLP-1 medication, not a painkiller, not a treatment for a structural injury, and not a stimulant, whatever the "cellular energy" language online suggests.

MOTS-c is encoded in the mitochondrial genome rather than the nucleus. The 2015 Cell Metabolism paper that identified it reported that in cultured cells it inhibits the folate cycle, causing a metabolite called AICAR to accumulate and activate AMPK — the low-fuel sensor exercise switches on — with skeletal muscle as the primary target. A 2021 Nature Communications paper reported better physical performance in treated mice at every age and, in humans, that exercise raises the body's own MOTS-c — an observational finding, which is why "exercise-mimetic" is a proposed mechanism, not a demonstrated effect in people. Fuller treatment on the MOTS-c page.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and nitric-oxide signalling, the axis the body uses to grow new blood vessels into healing tissue. A 2011 paper in the Journal of Applied Physiology reported increased growth hormone receptor expression and FAK–paxillin activation in cultured tendon fibroblasts — cells made more responsive to growth hormone already present, not growth hormone raised. Its largest literature concerns protection of the gut lining in animals. Fuller treatment on the BPC-157 page.

GHK-Cu is a tripeptide — glycine, histidine, lysine — bound to a copper ion, found in human plasma at levels reported to decline with age. The copper underpins most of its described effects, because collagen cross-linking and elastin formation are copper-dependent. Reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018) collect cell and animal work describing increased collagen, elastin and glycosaminoglycan synthesis, a shift in the balance between matrix metalloproteinases and their inhibitors, and support for angiogenesis. Fuller treatment on the GHK-Cu page.

Kisspeptin is the one component whose mechanism has been mapped in humans. It binds the KISS1R receptor on the hypothalamic neurons that release GnRH, which drives pituitary LH and FSH, which drive testosterone in the testes and oestrogen in the ovaries. A 2005 paper in the Journal of Clinical Endocrinology and Metabolism reported that intravenous kisspeptin-54 raised LH, FSH and testosterone in healthy men; kisspeptin-10 work in the same journal in 2011 reported a rise in LH and testosterone and more frequent LH pulses after a single bolus or short infusion. Kisspeptin receptors also sit in limbic brain regions, and a 2017 Journal of Clinical Investigation fMRI paper reported greater activation there in response to sexual and couple-bonding images during a kisspeptin-54 infusion — a direct action on the brain, separate from the hormone changes.

One property matters for scheduling: the Imperial College group reported that twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhoea stimulated the axis and then the response faded (JCEM 2009), while twice-weekly injections sustained it (Clinical Pharmacology and Therapeutics 2010). That tachyphylaxis is why a kisspeptin schedule is built around gaps. Fuller treatment on the kisspeptin page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding.

This rests on MOTS-c, and it is mouse work: the 2015 Cell Metabolism paper reported that treatment prevented age-related and diet-induced insulin resistance and weight gain, and the 2021 Nature Communications paper reported improved physical performance at every age, including with intermittent treatment started late in life. Human data is observational, plus one small early-phase company study of a modified analogue.

This rests on BPC-157. A 2003 paper in the Journal of Orthopaedic Research reported faster healing and better functional recovery of transected Achilles tendon in rats; muscle crush models report the same pattern. The largest literature is gastrointestinal: animal work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models.

GHK-Cu is the component with human skin studies of any size, but they are small studies of topical GHK-Cu on photoaged facial skin, plus one topical gel study in diabetic ulcers. None used the injectable form, whose evidence is animal work on wounds, connective tissue and lung inflammation.

Kisspeptin has more human data than any other component, and almost none of it tests kisspeptin-10 as used in this vial. Two randomised, double-blind, placebo-controlled crossover trials in JAMA Network Open — premenopausal women with hypoactive sexual desire disorder in 2022, men in 2023 — reported that a kisspeptin-54 infusion increased activation in sexual-processing brain regions on fMRI, and in men increased penile tumescence in response to sexual videos, versus placebo. They are real and randomised; they are also small, single-session, intravenous, used the 54-amino-acid form, and measured brain response rather than months of desire in daily life.

There are no randomised controlled trials of EUPHORIA, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• MOTS-c has no randomised controlled trials in humans; human data is observational plus one small company-reported Phase 1 study of a different analogue.
• BPC-157 has early-phase human work for inflammatory bowel indications, but no large randomised controlled trials and none for soft-tissue injury.
• GHK-Cu has small topical human studies and no randomised controlled trials of the injectable.
• Kisspeptin has small randomised trials for desire, but with kisspeptin-54, intravenously, in single sessions. There are no randomised controlled trials of a subcutaneous kisspeptin-10 course taken over weeks, which is how it is used here.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe EUPHORIA on. The accurate framing is "described in preclinical research, with human mechanistic work on one component, and used clinically" — not "proven in people."

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• That a subcutaneous kisspeptin-10 course raises testosterone or LH in a sustained way, or changes desire in daily life.
• That injected MOTS-c changes weight, glucose, fitness or energy in humans.
• An effect size or a timeline in humans for any component. Prescriber timelines are clinical experience, not trial endpoints.
• Long-term safety over years of use, or efficacy for any condition as an FDA-approved treatment. Neither EUPHORIA nor any component is approved for anything.

Kisspeptin-10 was placed in Category 2 of the FDA's interim 503A bulk drug substances list on 29 September 2023 — the category for nominated substances the FDA considers to raise significant safety risks. The FDA's published reasoning is that compounded drugs containing kisspeptin-10 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization," and that the agency "has no, or only limited, safety-related information for the proposed routes of administration."

On 29 October 2024 the FDA's Pharmacy Compounding Advisory Committee reviewed kisspeptin-10 for the nominated use of treating secondary hypogonadism in men. The FDA proposed that it not be included on the 503A Bulks List, and on the question of whether it should be placed on the list the committee voted 0 yes, 11 no, 0 abstaining.

Kisspeptin-10 remains in Category 2 as of September 2026. It was not among the peptides the FDA moved out of Category 2 in April 2026, was not on the agenda when the committee met on 23–24 July 2026, and is not among the five peptides the FDA has said the committee will consider before the end of February 2027. The FDA's current 503A list, updated 14 May 2026, gives Category 2 as cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. It names kisspeptin-10 only; other forms were never nominated.

Category 2 is an interim policy position, not a scheduling action or a ban on the molecule, and the FDA has not issued a final rule on kisspeptin-10. But the FDA's interim enforcement discretion for compounding with nominated substances, which covers Category 1, does not extend to Category 2.

Both sat in Category 2 from 2023. In April 2026 the FDA removed twelve peptides from Category 2 after their nominations were withdrawn, BPC-157 and MOTS-c among them; the FDA's Category 2 page, updated 22 April 2026, lists both as withdrawn. Removal lifts the safety-risk designation; it does not by itself place a substance on the positive 503A Bulks List.

On 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding both: BPC-157 (free base and acetate) by 8–6 with one abstention, for ulcerative colitis, and MOTS-c (free base and acetate) by 7–5 with two abstentions, for obesity and osteoporosis. FDA's own reviewers had recommended against inclusion in each case. A committee vote is a recommendation, not a decision; the FDA's determination is pending as of September 2026.

Injectable GHK-Cu was also removed from Category 2 in April 2026 and was not on the July agenda. The FDA's May 2026 list states that the agency "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list." Until then it is no longer flagged and not yet reviewed.

Three components are no longer restricted — two recommended for the positive list and awaiting final FDA action, one scheduled for review. The fourth, kisspeptin-10, remains in Category 2 after a unanimous advisory-committee vote against listing it, with no final rule issued. Neither the blend nor any component is an FDA-approved drug product, and compounded medications never are.

Most people notice little beyond injection-site tenderness. Kisspeptin's hormonal effect in the research is fast and short — LH rises within an hour and the peptide is cleared in minutes — so the early experience is described as unremarkable. Noticing nothing is normal.

Where changes in desire or mood are reported, this is when prescribers describe them appearing, consistent with the imaging work showing a direct limbic effect rather than a slow hormonal build. If hormonal support is the intent, this is when a physician would typically look at bloodwork, because no trial says what a weekday subcutaneous course does to testosterone over a month.

Where tissue-level change happens, this is where it would be expected to show, based on the animal timelines for BPC-157, and where prescribers say they would expect any MOTS-c effect — only alongside a training and nutrition plan, not instead of one. It typically takes a second vial to reach.

GHK-Cu's described effects on collagen and matrix are slow by nature; prescribers describe skin texture changes, where they occur, as a two-month-plus proposition. After a course there is no withdrawal and no rebound described for any component. Kisspeptin prompts the body's own axis rather than replacing its output, so there is no suppression to recover from — the opposite of external testosterone.

The directions are written in millilitres and insulin-syringe units because that is what you can read off the barrel: 0.25 mL is 25 units on a U-100 syringe, printed on your medication. Because the four are in fixed proportion, every dose delivers the same split. If directions and syringe markings appear to disagree, ask before dosing.

Into the fat layer, not the muscle; abdomen and thigh, rotated. Site does not matter for the kisspeptin or MOTS-c components, which act after absorption. The solution is blue — that is the copper in GHK-Cu, not a contaminant.

The two-day gap is not a missed dose: the kisspeptin research describes the response fading under continuous exposure and holding up when spaced, and the late-life MOTS-c mouse work used intermittent dosing. Twenty doses at five a week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile. Your physician may direct a different schedule.

Refrigerated, and it ships that way in insulated packaging with ice packs. Kisspeptin-10 is a short peptide sensitive to heat, light and temperature swings, so the label's storage directions are not optional. Beyond-use dating runs from first puncture.

Same molecule; the difference is one vial covering several aims, with each dose fixed by the blend's proportions. Kisspeptin alone is the cleaner choice when kisspeptin is the point, and the only way to change its amount independently.

Two components in common — BPC-157 and GHK-Cu at the same totals — and two that differ. KLOW adds TB-500 and KPV; GLOW adds TB-500 only. Both are repair and skin formulas with no metabolic or hormonal component. EUPHORIA swaps TB-500 for MOTS-c and adds kisspeptin-10, which makes it the broader formula and the only one of the three with a component still in FDA Category 2. If tissue repair is the actual goal, KLOW or GLOW is the more targeted prescription.

Both contain MOTS-c and BPC-157. FUSION pairs them with 5-Amino-1MQ and tesamorelin for body composition; EUPHORIA pairs them with GHK-Cu and kisspeptin-10 for energy, skin and hormonal signalling together. Neither has been studied as a blend, and neither comes as a pen.